Results 61 to 70 of about 29,702 (243)

Metabolic Signatures of Life Span Regulated by Mating, Sex Peptide and Mifepristone/RU486 in Female Drosophila melanogaster.

open access: yesThe journals of gerontology. Series A, Biological sciences and medical sciences, 2020
Mating and transfer of male Sex Peptide (SP), or transgenic expression of SP, causes inflammation and decreased life span in female Drosophila. Mifepristone rescues these effects, yielding dramatic increases in life span.
G. Landis   +15 more
semanticscholar   +1 more source

The new application of mifepristone in the relief of adenomyosis-caused dysmenorrhea

open access: yesInternational Journal of Medical Sciences, 2020
Background: Adenomyosis is a quite common gynecological disorder and above 30% of patients have typical secondary and progressive dysmenorrhea.
Xuan Che   +5 more
semanticscholar   +1 more source

C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins [PDF]

open access: yes, 2014
An expanded GGGGCC repeat in C9orf72 is the most common genetic cause of frontotemporal dementia and amyotrophic lateral sclerosis. A fundamental question is whether toxicity is driven by the repeat RNA itself and/or by dipeptide repeat proteins ...
Cabecinha, M   +19 more
core   +1 more source

Slow implementation of mifepristone medical termination of pregnancy in Quebec, Canada: a qualitative investigation

open access: yesEuropean journal of contraception & reproductive health care, 2020
Objectives: Mifepristone for first-trimester medical termination of pregnancy (MTOP) became available in Quebec in 2018, one year after the rest of Canada.
E. Guilbert   +7 more
semanticscholar   +1 more source

Post protocol residual thickness as a negative predictor for pharmacological treatment in early pregnancy loss

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective To determine the rate of pharmacological treatment failure in early pregnancy loss, assess post‐treatment residua thickness as a predictor of retained products of conception (RPOC), identify a clinically relevant cutoff, and evaluate additional clinical and sonographic predictors. Methods This retrospective cohort study was conducted
Ravit Pertez‐Machluf   +7 more
wiley   +1 more source

Modern approaches to the pre-induction cervical ripening of mifepristone

open access: yesРепродуктивная эндокринология, 2018
The article deals modern approaches used of mifepristone in order to prepare the cervix for delivery. The results of a study of 222 patients in the gestation period of 37–42 gestation weeks which given orally administered 200 mg of mifepristone at ...
О. В. Кравченко
doaj   +1 more source

A single-day treatment with mifepristone is sufficient to normalize chronic glucocorticoid induced suppression of hippocampal cell proliferation. [PDF]

open access: yesPLoS ONE, 2012
BACKGROUND: Chronic stress or prolonged administration of glucocorticoids suppresses proliferation and/or survival of newborn cells in adult rat dentate gyrus.
Pu Hu   +6 more
doaj   +1 more source

Medication Abortion: A Sample Protocol for Increasing Access During a Pandemic and Beyond [PDF]

open access: yes, 2021
No ...
Atrio, Jessica   +10 more
core  

Risk factors, predictive markers and prevention strategies for intrauterine fetal death. An integrative review [PDF]

open access: yes, 2020
According to World Health Organization (WHO), fetal death is defined as the death of the fetus prior to its complete expulsion, independent of the duration of pregnancy, thus only ascribing the term stillbirth to fetal deaths in the case of pregnancies ...
Andronache, Liliana Florina   +6 more
core   +2 more sources

Mifepristone followed by misoprostol compared with placebo followed by misoprostol as medical treatment for early pregnancy loss (the Triple M trial): A double-blind placebo-controlled randomised trial

open access: yesGeburtshilfe und Frauenheilkunde, 2020
Background Worldwide, millions of women seek treatment for early pregnancy loss (EPL) annually. Medical management with misoprostol is widely used, but only effective 60% of the time. Pre-treatment with mifepristone prior to misoprostol might improve the
C. Hamel   +15 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy